Monika Buraczynska

Monika Buraczynska

Auto-generated profile, based on publicly available information

Monika Buraczynska

Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Dr K. Jaczewskiego 8, 20-954 Lublin, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2007 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
MBM. Buraczynska
M. Buraczynska
PKP. Ksiazek
P. Ksiazek
IBI. Baranowicz-Gaszczyk
I. Baranowicz-Gaszczyk
LJL. Jozwiak
L. Jozwiak
Diabetic microvascular complications are the major causes of morbidity and early mortality in diabetes. Vascular endothelial growth factor (VEGF) is a potent multifunctional cytokine which plays a key role in the pathogenesis of diabetic microvascular complications. We examined the possible association of the VEGF gene polymorphisms with diabetic nephropathy and retinopathy in type 2 diabetes patients. Genotyping of the VEGF gene insertion/deletion (I/D) and +405 polymorphisms was done by the polymerase chain reaction (PCR) and restriction fragment length polymorphism methods. A total of 426 patients with type 2 diabetes and 493 healthy subjects were genotyped. The frequency of VEGF alleles and genotype distribution were compared in diabetic and control groups. The distribution of the VEGF DD genotype was significantly different in patients with diabetic retinopathy compared with healthy controls, entire diabetic group and patients with no complications (44 vs. 23, 30 and 21%, respectively; P < 0.01). Such differences were not observed in the diabetic nephropathy group. The odds ratio for the D allele was 2.27 (95% CI 1.59-3.25). The multivariate logistic regression analysis revealed that the D allele of the VEGF gene I/D polymorphism was an independent risk factor of retinopathy (P < 0.001). The VEGF +405 genotype was not associated with diabetic complications in type 2 diabetes patients. Our study suggests that the I/D polymorphism in the promoter region of the VEGF gene is associated with retinopathy but not nephropathy in type 2 diabetes patients. The multivariate logistic regression analysis showed that the D allele of the VEGF polymorphism is an independent risk factor of diabetic retinopathy after controlling for other clinical variables.

2 October 2011 in NeuroMolecular Medicine
Verified
Journal Article
Open access
PDF file
MBMonika Buraczynska
Monika Buraczynska
PZPawel Zukowski
Pawel Zukowski
KBKinga Buraczynska
Kinga Buraczynska
SMSlawomir Mozul
Slawomir Mozul
AKAndrzej Ksiazek
Andrzej Ksiazek
Renalase is a novel, recently identified, flavin adenine dinucleotide-dependent amine oxidase. It is secreted by the kidney and metabolizes circulating catecholamines. Renalase has significant hemodynamic effects, therefore it is likely to participate in the regulation of cardiovascular function.The aim of our study was to investigate the involvement of renalase gene polymorphisms in hypertension in type 2 diabetes patients. A total of 892 patients and 400 controls were genotyped with three SNPs in the renalase gene. The C allele of rs2296545 SNP was associated with hypertension (P < 0.01). For rs2576178 SNP, frequencies in hypertensive patients differed from controls, but not from normotensive patients. For rs10887800 SNP, the differences in the G allele frequencies were observed in hypertensive patients with stroke, with 66% of patients being GG homozygotes. To confirm observed association we later genotyped 130 stroke patients without diabetes. The OR for risk allele was 1.79 (95% CI 1.33–2.41). In conclusion, the renalase gene polymorphism was associated with hypertension in type 2 diabetes patients. The most interesting result is a strong association of the rs10887800 polymorphism with stroke in patients with and without diabetes. The G allele of this polymorphism might thus be useful in identifying diabetes patients at increased risk of stroke.

29 December 2005 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MBMonika Buraczynska
Monika Buraczynska
PKPiotr Ksiazek
Piotr Ksiazek
ADAndrzej Drop
Andrzej Drop
WZWojciech Zaluska
Wojciech Zaluska
DSDanuta Spasiewicz
Danuta Spasiewicz
AKAndrzej Ksiazek
Andrzej Ksiazek
Background. End-stage renal disease (ESRD) is a complex phenotype resulting from underlying kidney diseases of different etiologies as well as from environmental and genetic factors. The responsible genes influencing the development and rate of progression to ESRD have yet to be defined. We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients. Methods. Genotyping was performed in 745 ESRD patients and 520 control subjects for the angiotensin-converting enzyme (ACE) I/D, angiotensinogen (AGT) M235T and angiotensin II type 1 receptor (AT1R) A1166C gene polymorphisms using polymerase chain reaction and gel analysis. Results. Allele and genotype frequencies of the ACE polymorphism did not differ significantly between ESRD patients and controls. The patient group showed an increased frequency of the T allele of the AGT polymorphism (P = 0.02) and the C allele and CC genotype of the AT1R polymorphism (P<0.01). There was an association of the AT1R gene polymorphism with the progression of renal disease to end-stage failure. The time from diagnosis to the onset of ESRD was significantly shorter in patients carrying the C allele than in subjects with the homozygous AA genotype (4.7 years vs 12.6 years, P<0.001). The observed effect was not associated with hypertension in studied subjects. Conclusion. The results of our study demonstrate the association between the AT1R A/C polymorphism and renal disease progression. The CC/AC genotype of this polymorphism might serve as a predictor for early ESRD and might be useful in planning therapeutic strategies for individual patients.

1 February 2009 in Human Immunology
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
IBIwona Baranowicz-Gaszczyk
Iwona Baranowicz-Gaszczyk
JTJerzy Tarach
Jerzy Tarach
AKAndrzej Ksiazek
Andrzej Ksiazek

1 September 2011 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
ASAndrzej Swatowski
Andrzej Swatowski
DMDorota Markowska-Gosik
Dorota Markowska-Gosik
AKAgata Kuczmaszewska
Agata Kuczmaszewska
AKAndrzej Ksiazek
Andrzej Ksiazek

31 August 2007 in Translational Research
Verified
Journal Article
Closed access
MBMonika Buraczynska
Monika Buraczynska
LJLucyna Jozwiak
Lucyna Jozwiak
PKPiotr Ksiazek
Piotr Ksiazek
EBEwa Borowicz
Ewa Borowicz
PMPiotr Mierzicki
Piotr Mierzicki